Loading for you the most updated information... |
Related posters/abstract
{jumi *1010}{/jumi}
HuBase®
Due to the explosive growth in the more clinical relevant human primary tumorgraft models such as CrownBio’s HuPrime® collection, it is becoming increasingly important to be able to translate the unique profiles of each patient model and its specific tumor attributes into improving clinical trial designs. The HuBase® database, a web-based data-mining platform, is aiming to close this gap by providing expanding depth in the databases contents including ; transcription profiling data, Oncogene SNP data, CNV, mutational status, IHC data sets, clinical histories, tumor growth and passage characteristics, etc. Stay update here or write us to check on your specific gene of interest!
| Tumor Type | Total Sample | IHC | Affy txp profiling | Cancer SNP | Gene mutation | Diagnostic and clinical | SOC data | Growth Data | Whole-genome CNV |
|---|---|---|---|---|---|---|---|---|---|
| Lung Cancer | 11 | 9 | 11 | 11 | 11 | 11 | 3 | 11 | 4.15.2011 |
| Gastric Cancer | 29 | 24 | 30 | 28 | 29 | 5 | 5 | 29 | 4.15.2011 |
| Head and Neck Cancer | 4 | 3 | 4 | 3 | 4 | 4 | 1 | 4 | 4.15.2011 |
| Colorectal Cancer | 20 | 20 | 5 | 4 | 5 | 5 | 3 | 5 | 4.15.2011 |
| Esophageal Cancer | 22 | 18 | 22 | 19 | 22 | 3 | 2 | 22 | 4.15.2011 |
| Liver Cancer | 7 | 7 | 7 | 7 | 7 | 4 | 4 | 7 | 4.15.2011 |
| Kidney Cancer | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 4.15.2011 |
| Ovarian Cancer | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 4.15.2011 |
| Sarcoma | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 4.15.2011 |
| Pancreatic Cancer | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4.15.2011 |
| Prostate Cancer | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4.15.2011 |
| Adrenal Gland Cancer | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4.15.2011 |
| Unknown | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 4.15.2011 |
| Lymphoma | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4.15.2011 |
| Gall Bladder Cancer | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4.15.2011 |
| TOTAL | 109 | 97 | 79 | 72 | 78 | 32 | 18 | 78 | 62.25 |
HuKemia®
HuKemia® is the world’s first and only collection of human primary hematological models available for efficacy testing and ex vivo screening. With growing collections of AML, ALL, CLL,CML, Nonhodgkin’s lymphoma, multiple myeloma, mantle cell patient samples, CrownBio extends its translational research platforms for oncology research. Complete with outcome data, these established and validated hematologic models for human leukemias mimic the clinical disease and enable the kinetics, characteristics and chemosensitivity of leukemia to be sequentially monitored in individual immunodeficient mouse model.
| Disease Type | Primary BM Sample | Fit for Efficacy Testing |
|---|---|---|
| AML | 133 | 28 |
| AML | 45 | 18 |
| MM | 51 | 12 |
| CML | 17 | 10 |
| Myelodysplastic syndromes (MDS) | 4 | 0 |
| CLL | 2 | 0 |
| TOTAL | 252 | 68 |
LIVING TISSUE™ BANK
huprime_seal_bwCurrent pre-clinical cancer animal models are poorly predictive in clinical efficacy, and have limited value in predicting disease indications in humans. Primary tumor tissue offers a valuable resource for biomarker identification, as well as a better alternative for preclinical drug evaluation. However, accessing sufficient high quality tumor tissue remains a significant challenge for translational research. Furthermore, establishing testing systems from primary tumor samples is often cost inhibitive due to low success rate and high labor intensity in the process. CrownBio’s Asian infrastructure and unlimited capacity can JumpStart™ your human primary tumorgraft efficacy testing today!| Tumor Type | Total Cases | P0 | P1 | P2 | P3 |
|---|---|---|---|---|---|
| Adrenal gland | 6 | 1 | 1 | 1 | 1 |
| Brain | 23 | 2 | 2 | 2 | 1 |
| Bile Duct | 3 | 0 | 0 | 0 | 0 |
| Bladder | 20 | 1 | 1 | 1 | 1 |
| Breast | 121 | 2 | 2 | 2 | 2 |
| Testis | 1 | 1 | 0 | 0 | 0 |
| Cervical | 7 | 0 | 0 | 0 | 0 |
| Chondromyxoid Fibroma | 1 | 0 | 0 | 0 | 0 |
| Colorectal | 64 | 28 | 23 | 21 | 21 |
| Endometrial | 6 | 0 | 0 | 0 | 0 |
| Esophageal | 63 | 28 | 28 | 28 | 28 |
| Fallopian | 1 | 1 | 1 | 1 | 1 |
| Gallbladder | 6 | 3 | 3 | 3 | 3 |
| Gastric | 107 | 30 | 30 | 30 | 30 |
| Head and Neck | 99 | 8 | 8 | 7 | 5 |
| Inflammatory Myofibroblastic Tumor | 1 | 0 | 0 | 0 | 0 |
| Kidney | 75 | 3 | 3 | 2 | 2 |
| Liver | 257 | 19 | 15 | 13 | 11 |
| Lung | 218 | 22 | 22 | 17 | 17 |
| Lymphoma | 7 | 1 | 1 | 1 | 1 |
| Mediastinal | 2 | 0 | 0 | 0 | 0 |
| Metastatic Carcinoma | 3 | 3 | 3 | 3 | 3 |
| Ovarian | 27 | 5 | 5 | 4 | 4 |
| Pancreatic | 28 | 6 | 5 | 5 | 3 |
| Prostate | 16 | 1 | 1 | 1 | 1 |
| Sarcoma | 13 | 5 | 5 | 5 | 5 |
| Thymoma | 2 | 0 | 0 | 0 | 0 |
| MIXED | 31 | 1 | 1 | 1 | 1 |
| TOTAL | 1208 | 171 | 160 | 148 | 141 |
Unique Assets Expansion and Updates
CrownBio is the only CRO with the financial commitment to expand our current collection of human primary tumorgrafts across not only tumor types with unmet clinical needs but extends it to all cancer types and all ethnicities. With over 121 established HuPrime® models fit for efficacy testing today, and an extensive genomic and proteomic data set, HuBase™ ; we can reduce your need for large efficacy studies by providing SMARTER™ model selection..
Dedicated to providing the highest quality, and most reliable xenograft animal models of all contract research outsource service providers, CrownBio is now the gold standard for efficacy testing and new model generation. Complete with guaranteed growth curves, SOC response curves, lower animal numbers per grouping, and unparalleled surgical expertise ; our ValidatedXeno™ collection is expanding an average of 4 new models per month..
HuKemia® is the world’s first and only collection of human primary hematological models available for efficacy testing and ex vivo screening. With growing collections of AML, ALL, CLL,CML, Nonhodgkin’s lymphoma, multiple myeloma, mantle cell patient samples, CrownBio extends its translational research platforms for oncology research. Complete with outcome data, these established and validated hematologic models for human leukemias mimic the clinical disease and enable the kinetics, characteristics and chemosensitivity of leukemia to be sequentially monitored in individual immunodeficient mouse model.
Due to the explosive growth in the more clinical relevant human primary tumorgraft models such as CrownBio’s HuPrime® collection, it is becoming increasingly important to be able to translate the unique profiles of each patient model and its specific tumor attributes into improving clinical trial designs. The HuBase® database, a web-based data-mining platform, is aiming to close this gap by providing expanding depth in the databases contents including: expression profiling, CNV data, mutation status, biomarker protein expression datasets, clinical histories, tumor growth and passage characteristics, etc. Stay up to date or call us for a free trial subscription.
PRESS RELEASE
Media for download
Press Releases
Crown Bioscience Introduces New Informational Site Feature
July 2010
Download: 
PR_14.pdf (823 Kb)
Crown Bioscience Adds Former Distinguished Eli Lilly Scholar to its Senior Management Team
March 2010
Download: (822 Kb) PR_13.pdf
Pfizer chooses Crown Bioscience as partner
December 2009
Download: PR_12.pdf (1.26 Mb)
New Site Designed Around Customers’ Needs
August 2008
Download: PR_11.pdf (804 Kb)
Crown Bio expands to translational medicine and predictive biology
July 2008
Download: PR_10.pdf (809 Kb)
Company completes facility expansion
May 2008
Download: Please contact us in order to download the file
Chemizon Participates in Crown Bioscience
April 2008
Download: PR_01.pdf (794 Kb)
Dr. Michelle Xia joins CrownBio as the Vice President of Protein Science
March 2008
Download: Please contact us in order to download the file
Formal accreditation letter from AAALAC
February 2008
Download: Please contact us in order to download the file
April 5, 2013
Crown Bioscience, Inc. and Horizon Discovery Announce Exclusive Two Year Agreement to Offer Combined Solutions for In Vivo Drug Discovery Model Development
Santa Clara, CA (April 3rd 2013) – Crown Bioscience, Inc. (Crown), a leading global drug discovery and development service company, and Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, today announced they have signed an exclusive two year collaboration agreement. Under the terms of the agreement Crown will be given access to Horizon’s proprietary collection of X-MAN isogenic cell lines to develop novel in vivo models for drug discovery.Download: Crown Bioscience Horizon Agreement PR
November 6, 2012
Crown Bioscience, Inc. and Horizon Discovery, Ltd. announce the availability of X-MAN Cell Lines for In Vivo and In Vitro Drug Discovery Model Validation
Santa Clara, CA. November 06, 2012 - Leveraging their unique drug discovery and translational research platforms, Crown Bioscience and Horizon Discovery today announced the availability of X-MAN cell lines in vivo as well as in vitro, to facilitate the development of novel oncology targets and early-stage drug discovery programs within the pharmaceutical industry…
Download: Crown Bioscience EORTC PR for Crown_Horizon final
January 11, 2012
Crown Bioscience, Inc. Enters into Strategic Partnership with Jiangsu Hengrui Medicine Co., Ltd. for the Discovery and Commercialization of Novel Therapeutic Monoclonal Antibodies
Santa Clara, CA (PRWEB) January 11, 2012 - Crown Bioscience, Inc., a leading global drug discovery company, and Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui"), a major Chinese pharmaceutical company, today announced that CrownBio Taicang Biologics Division, a wholly owned subsidiary of Crown Bioscience, Inc., and Hengrui have entered into a strategic partnership for the discovery and commercialization of a novel therapeutic monoclonal antibody ("mAb") for the Chinese and global market.
Download:
Crown Bioscience Inc Enters into Strategic Partnership with Jiangsu Hengrui..Jan 11, 2012 pdf
September 7, 2011
Crown Bioscience Expands Distribution Network - Appoints On Target Co, Ltd. as Sales Representative in Japan to Enable Access to Translational Oncology Assets
Santa Clara, California (PRWEB) August 11, 2011 -- Japan's pharmaceutical and biotech drug development programs gain easy access and technical support of CrownBio's unique translational oncology assets HuPrime® and HuBase™ with Japan's premier technical sales organization On Target.
Download: CrownBio-On Target Press Release pdf
May 4, 2011
Crown Bioscience, Inc. Announces Closing of Series C Financing
SANTA CLARA, Calif., May 4, 2011 /PRNewswire/ -- Crown Bioscience, Inc., a leading company in innovative oncology R&D partnership and services, today announced the closing of a US$28.8 million Series C financing. The proceeds will be used for expanding services in integrated cancer drug discovery and translational oncology, as well as to fund new initiatives in other therapeutic areas.
Download: Crown-Bioscience-Inc-prnews-3307799797.pdf
EVENTS & SHOWS
We want to meet you! Meet our Experts to discuss their posters, and technology advances. CrownBio often sponsors young investigators, and offers complimentary show passes, so if we are where you want to be, contact us.
Full list of eventsPrevious Events
- BIO2011 (June 2011)
- American Diabetes Association (June 2011)
- ASCO (June 2011)
- Pegs (May 2011)
- AACR (April 2011)
- Cancer Stem Cell Meeting (March 2011)
- Bio North America (February 2011)
- TRI-Conference (February 2011)
- PepTalk (January 2011)
- ASH (December 2010)
- AACR/EROTC (November 2010)
- Planet Connect (November 2010)
- Biopartnering Europe (October 2010)
- Contract Pharma (September 2010)
- Translational Cancer Medicine (July 2010)
- American Diabetes Association (June 2010)
- Structure Base Drug Design (June 2010)
- AACR - American Association for Cancer Research (April 2010)
- BioPartnering North America™ (January 2010)
- Peptalk 2010 (January 2010)
- 51st ASH Annual Meeting and Exposition 2009 (December 2009)
- Contract Pharma (September 2009)
- DDT - Drug Discovery & Development (August 2009)
- ASCO 2009 (June 2009)
- Protein Kinase Targets 2009 (June 2009)
- Biomarker (May 2009)
- Bio 2009 - The Global Event for Biotechnology (May 2009)
- China 2009 Pharmaceutical R&D Summit (April 2009)
- NewGeneration Pharmaceuticals (April 2009)
- PEGS summit (April 2009)
- PEP TALK - The Definitive Protein-Focused Event (January 2009)
- EORTC - symposium (October 2008)
- Contract Pharma (September 2008)
- DDT - Drug Discovery & Development (September 2008)
- EACR - The European Association for Cancer Research (June 2008)
- ASCO - American Society of Clinical Oncology (May 2008)
- AACR Anual meeting ( 0)
Career Opportunities
If you love the intellectual challenge of working in a fast-paced, results-driven organization, there is a home for you at Crown Biosciences. For consideration of any of the open positions below, simply click on the title and follow the link to upload your cv. If you have any questions for the Human Resources Department, please e-mail hr@crownbio.com .We look forward to meeting you!
